Tofidence for Autoimmune Diseases FDA approved Tofidence (tocilizumab-bavi) as biosimilar to U.S.-licensed Actemra (tocilizumab) . This product is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system. Tofidence is approved for the following indications currently approved for U.S.-licensed Actemra: Rheumatoid
The landscape of rheumatological treatments has witnessed significant advancements in the past few decades. One notable milestone is the introduction of biosimilars, which have the potential to revolutionize the approach to managing a myriad of rheumatologic conditions. But what exactly are biosimilars, and how do they fare in terms of
Biologic infusions offer highly specialized and targeted treatments for many rheumatologic conditions. Historically, such treatments were confined to hospitals or infusion centers, which increase patient handoffs and cost of care. In-office infusion centers have many advantages for providers and their patients. They offer patients flexibility and convenience but also ensure
Biologics are here to stay. With 60% of current pipeline therapies falling into the infused or injected category, this niche of medicine is not going away. From asthma and allergy to migraines and gout, Crohn’s, and everything in between, there are few chronic disease states not touched by biologics.